Outcome Of 673 Patients With Hematologic Malignancies Surviving At Least 8 Years Post- Allogeneic Transplants: Risk Factors And Quality Of Life

Giuseppe Sapienza,Teresa Lamparelli,Alida Dominietto,Anna Maria Raiola,Carmen Di Grazia,Francesca Gualandi,Simona Sica,Elisabetta Metafuni,Emanuele Angelucci,Andrea Bacigalupo

BLOOD（2019）

引用 0|浏览44

暂无评分

摘要

Background : Allogeneic hemopoietic stem cell transplantation (HSCT) has been widely used in hematologic malignancies for over 4 decades. One important question is the longterm outcome of these patients, in terms of leukemia control and quality of life.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要